The war in Ukraine continues to cause suffering and hardship. The Polish and the German Red Cross – also supported by donations from us – help to the best of their ability.
Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
Phase 3 studies survodutide obesity and overweight
Phase 3 studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease
FDA grants Fast Track designation for the treatment of chronic kidney disease, underscoring urgent need for new treatments for people living with the condition
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.